Basel Medical
BMGL
2 hedge funds and large institutions have $3.44K invested in Basel Medical in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0.01% more ownership
Funds ownership: 0.02% → 0.03% (+0.01%)
50% less funds holding
Funds holding: 4 → 2 (-2)
89% less capital invested
Capital invested by funds: $32.2K → $3.44K (-$28.8K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$15.7K |
| 2 |
TC
T3 Companies
New York
|
-$8.85K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.36K |
BMGL Hedge Fund Activity: Q2 2026 in Review
2 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in Basel Medical (BMGL) for Q2 2026, worth a combined $3.44K — down 89% from $32.2K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BMGL and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was XTX Topco, exiting entirely with an estimated $15.7K sold.
- 2 institutional investors held Basel Medical (BMGL) as of Q2 2026, down from 4 in Q1 2026.
- Funds reported $3.44K of Basel Medical stock for Q2 2026, down 89% quarter-over-quarter.
- 0 funds opened new Basel Medical positions in Q2 2026 and 2 closed out, a net change of -2 holders.
- The largest Basel Medical seller in Q2 2026 was XTX Topco, an estimated $15.7K sold.
Based on aggregated 13F filings for Q2 2026.